Synthetic DNA vaccines: Improved vaccine potency by electroporation and co-delivered genetic adjuvants

Frontiers in Immunology

Volumn 4, Issue NOV, 2013, Pages

  Flingai, Seleeke ^a   Czerwonko, Matias ^a,b   Goodman, Jonathan ^a   Kudchodkar, Sagar B ^a   Muthumani, Kar ^a   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSIDAD AUSTRAL   (Argentina)

Author keywords

Adjuvants; DNA vaccine; Electroporation; Interleukin 12; Plasmid

Indexed keywords

DNA VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN; PLASMID DNA;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; DNA IMMUNIZATION; DNA TRANSFER; ELECTROPORATION; GENE EXPRESSION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; PLASMID; PROCESS OPTIMIZATION; REVIEW; SAFETY; SOMATIC CELL; T LYMPHOCYTE;

EID: 84890346971     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00354     Document Type: Review

References (141)

1. Stewart AJ, Devlin PM. The history of the smallpox vaccine. J Infect (2006) 52:329-34. doi:10.1016/j.jinf.2005.07.021
2. Galambos L. A century of innovation in vaccines. Vaccine (1999) 17:S7-10. doi:10.1016/S0264-410X(99)00287-X
3. Plotkin SA. Vaccines: the fourth century. Clin Vaccine Immunol (2009) 16:1709-19. doi:10.1128/CVI.00290-09
4. Atanasiu P, Orth G, Rebiere JP, Boiron M, Paoletti C. Production of tumors in the hamster by inoculation of desoxyribonucleic acid extracted from tissue cultures infected with polyoma virus. C R Hebd Seances Acad Sci (1962) 254:4228-30.
5. Orth G, Atanasiu P, Boiron M, Rebiere JP, Paoletti C. Infectious and oncogenic effect of DNA extracted from cells infected with polyoma virus. Proc Soc Exp Biol Med (1964) 115:1090-5. doi:10.3181/00379727-115-29124
6. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science (1990) 247:1465-8. doi:10.1126/science.1690918
7. Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol (2001) 75:4040-7. doi:10.1128/JVI.75.9.4040-4047.2001
8. Garver KA, LaPatra SE, Kurath G. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. Nerka salmon. Dis Aquat Organ (2005) 64:13-22. doi:10.3354/dao064013
9. Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine (2006) 24:4582-5. doi:10.1016/j.vaccine.2005.08.027
10. Draghia-Akli R, Ellis KM, Hill LA, Malone PB, Fiorotto ML. High-efficiency growth hormone-releasing hormone plasmid vector administration into skeletal muscle mediated by electroporation in pigs. FASEB J (2003) 17:526-8. doi:10.1096/fj.02-0671fje
11. Stasney J, Paschkis KE, Cantarow A, Morris HP. The production of neoplasms by the injection of chromatin fractions. Acta Unio Int Contra Cancrum (1955) 11:715-20.
12. Paschkis KE, Cantarow A, Stasney J. Induction of neoplasms by injection of tumor chromatin. J Natl Cancer Inst (1955) 15:1525-32.
13. Ito Y. A tumor-producing factor extracted by phenol from papillomatous tissue (Shope) of cottontail rabbits. Virology (1960) 12:596-601. doi:10.1016/0042-6822(60)90182-3
14. Israel MA, Chan HW, Hourihan SL, Rowe WP, Martin MA. Biological activity of polyoma viral DNA in mice and hamsters. J Virol (1979) 29:990-6.
15. Will H, Cattaneo R, Darai G, Deinhardt F, Schellekens H, Schaller H. Infectious hepatitis B virus from cloned DNA of known nucleotide sequence. Proc Natl Acad Sci U S A (1985) 82:891-5. doi:10.1073/pnas.82.3.891
16. Benvenisty N, Reshef L. Direct introduction of genes into rats and expression of the genes. Proc Natl Acad Sci U S A (1986) 83:9551-5. doi:10.1073/pnas.83.24.9551
17. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature (1992) 356:152-4. doi:10.1038/356152a0
18. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 259:1745-9. doi:10.1126/science.8456302
19. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A (1993) 90:11478-82. doi:10.1073/pnas.90.24.11478
20. Wang B, Ugen KE, Srikantan V, Agadjanyan MG, Dang K, Refaeli Y, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1993) 90:4156-60. doi:10.1073/pnas.90.9.4156
21. Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis (2007) 296:1732-40. doi:10.1086/523650
22. Ledgerwood JE, Pierson TC, Hubka SA, Desai N, Rucker S, Gordon IJ, et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase 1 clinical trial. J Infect Dis (2011) 203:1396-404. doi:10.1093/infdis/jir054
23. Anderson ED, Mourich DV, Fahrenkrug SC, LaPatra S, Shepherd J, Leong JA. Genetic immunization of rainbow trout (Oncorhynchus mykiss) against infectious hematopoietic necrosis virus. Mol Mar Biol Biotechnol (1996) 5:114-22.
24. Corbeil S, Lapatra SE, Anderson ED, Jones J, Vincent B, Hsu YL, et al. Evaluation of the protective immunogenicity of the N, P, M, NV and G proteins of infectious hematopoietic necrosis virus in rainbow trout Oncorhynchus mykiss using DNA vaccines. Dis Aquat Organ (1999) 22:29-36. doi:10.3354/dao039029
25. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res (2003) 9:1284-90.
26. Khan AS, Bodles-Brakhop AM, Fiorotto ML, Draghia-Akli R. Effects of maternal plasmid GHRH treatment on offspring growth. Vaccine (2010) 28:1905-10. doi:10.1016/j.vaccine.2009.10.093
27. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med (1996) 2:1122-8. doi:10.1038/nm1096-1122
28. Chattergoon MA, Robinson TM, Boyer JD, Weiner DB. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. J Immunol (1998) 160:5707-18.
29. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med (1999) 189:169-78. doi:10.1084/jem.189.1.169
30. Dupuis M, Denis-Mize K, Woo C, Goldbeck C, Selby MJ, Chen M, et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J Immunol (2000) 165:2850-8.
31. Rubartelli A, Poggi A, Zocchi MR. The selective engulfment of apoptotic bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extracellular calcium. Eur J Immunol (1997) 27:1893-900. doi:10.1002/eji.1830270812
32. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med (1998) 188:1359-68. doi:10.1084/jem.188.7.1359
33. Eschenburg G, Stermann A, Preissner R, Meyer HA, Lode HN. DNA vaccination: using the patient's immune system to overcome cancer. Clin Dev Immunol (2010) 2010:169484. doi:10.1155/2010/169484
34. Brown F. Review of accidents caused by incomplete inactivation of viruses. Dev Biol Stand (1993) 81:103-7.
35. Kew O, Morris-Glasgow V, Landaverde M, Burns C, Shaw J, Garib Z, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science (2002) 296:356-9. doi:10.1126/science.1068284
36. Cattamanchi A, Posavad CM, Wald A, Baine Y, Moses J, Higgins TJ, et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol (2008) 15:1638-43. doi:10.1128/CVI.00167-08
37. Manam S, Ledwith BJ, Barnum AB, Troilo PJ, Pauley CJ, Harper LB, et al. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology (2000) 43:273-81. doi:10.1159/000053994
38. Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, Griffiths TG II, et al. Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology (2000) 43:258-72. doi:10.1159/000053993
39. Klinman DM, Takeshita F, Kamstrup S, Takeshita S, Ishii K, Ichino M, et al. DNA vaccines: capacity to induce auto-immunity and tolerance. Dev Biol (Basel) (2000) 104:45-51.
40. MacGregor RR, Boyer JD, Ciccarelli RB, Ginsberg RS, Weiner DB. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data. J Infect Dis (2000) 181:406. doi:10.1086/315199
41. Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol (2005) 79:771-9. doi:10.1128/JVI.79.2.771-779.2005
42. Mamula M. Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes. Immunol Rev (1998) 164:231-9. doi:10.1111/j.1600-065X.1998.tb01223.x
43. Isaguliants MG, Iakimtchouk K, Petrakova NV, Yermalovich MA, Zuber AK, Kashuba VI, et al. Gene immunization may induce secondary antibodies reacting with DNA. Vaccine (2004) 22:1576-85. doi:10.1016/j.vaccine.2003.09.033
44. Moreau P, Hen R, Wasylyk B, Everett R, Gaub MP, Chambon P. The SV40 72 base repair repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants. Nucleic Acids Res (1981) 9:6047-68. doi:10.1093/nar/9.22.6047
45. Gorman CM, Merlino GT, Willingham MC, Pastan I, Howard BH. The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc Natl Acad Sci U S A (1982) 79:6777-81. doi:10.1073/pnas.79.22.6777
46. Chatellard P, Pankiewicz R, Meier E, Durrer L, Sauvage C, Imhof MO. The IE2 promoter/enhancer region from mouse CMV provides high levels of therapeutic protein expression in mammalian cells. Biotechnol Bioeng (2007) 96:106-17. doi:10.1002/bit.21172
47. Qin JY, Zhang L, Clift KL, Hulur I, Xiang AP, Ren BZ, et al. Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS One (2010) 5:e10611. doi:10.1371/journal.pone.0010611
48. Qin L, Ding Y, Pahud DR, Chang E, Imperiale MJ, Bromberg JS. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther (1997) 8:2019-29. doi:10.1089/hum.1997.8.17-2019
49. Darnell JE Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (1994) 264:1415-21. doi:10.1126/science.8197455
50. Vanniasinkam T, Reddy ST, Ertl HC. DNA immunization using a non-viral promoter. Virology (2006) 344:412-20. doi:10.1016/j.virol.2005.08.040
51. Luo P, Reed BD, Tsang TC, Harris DT, Flavell RA. A self-augmenting gene expression cassette for enhanced and sustained transgene expression in the presence of proinflammatory cytokines. DNA Cell Biol (2006) 25:659-67. doi:10.1089/dna.2006.25.659
52. Shepherd CT, Scott MP. Construction and evaluation of a maize (Zea mays) chimeric promoter with activity in kernel endosperm and embryo. Biotechnol Appl Biochem (2009) 52:233-43. doi:10.1042/BA20070269
53. Harton JA, Ting JP. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol (2000) 20:6185-94. doi:10.1128/MCB.20.17.6185-6194.2000
54. Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, Truitt DM, et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol (2005) 79:8828-34. doi:10.1128/JVI.79.14.8828-8834.2005
55. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol (1987) 196:947-50. doi:10.1016/0022-2836(87)90418-9
56. Olafsdóttir G, Svansson V, Ingvarsson S, Marti E, Torsteinsdóttir S. In vitro analysis of expression vectors for DNA vaccination of horses: the effect of a Kozak sequence. Acta Vet Scand (2008) 50:44. doi:10.1186/1751-0147-50-44
57. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet (2008) 9:776-88. doi:10.1038/nrg2432
58. Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol (2004) 22:346-53. doi:10.1016/j.tibtech.2004.04.006
59. Uchijima M, Yoshida A, Nagata T, Koide Y. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. J Immunol (1998) 161:5594-9.
60. Muthumani K, Kudchodkar S, Zhang D, Bagarazzi ML, Kim JJ, Boyer JD, et al. Issues for improving multiplasmid DNA vaccines for HIV-1. Vaccine (2002) 20:1999-2003. doi:10.1016/S0264-410X(02)00086-5
61. Ramakrishna L, Anand KK, Mohankumar KM, Ranga U. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization. J Virol (2004) 78:9174-89. doi:10.1128/JVI.78.17.9174-9189.2004
62. Frelin L, Ahlén G, Alheim M, Weiland O, Barnfield C, Liljeström P, et al. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Ther (2004) 11:522-33. doi:10.1038/sj.gt.3302184
63. Cheung YK, Cheng SC, Sin FW, Xie Y. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Vaccine (2004) 23:629-38. doi:10.1016/j.vaccine.2004.07.010
64. Siegismund CS, Hohn O, Kurth R, Norley S. Enhanced Tzand B-cell responses to simian immunodeficiency virus (SIV)agm, SIVmac and human immunodeficiency virus type 1 Gag DNA immunization and identification of novel T-cell epitopes in mice via codon optimization. J Gen Virol (2009) 90:2513-8. doi:10.1099/vir.0.013730-0
65. Tenbusch M, Grunwald T, Niezold T, Storcksdieck Genannt Bonsmann M, Hannaman D, Norley S, et al. Codon-optimization of the hemagglutinin gene from the novel swine origin H1N1 influenza virus has differential effects on CD4(+) T-cell responses and immune effector mechanisms following DNA electroporation in mice. Vaccine (2010) 28:3273-7. doi:10.1016/j.vaccine.2010.02.090
66. Holmström F, Pasetto A, Nähr V, Brass A, Kriegs M, Hildt E, et al. A synthetic codon-optimized hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T cell responses in wild-type and NS5A-transgenic mice. J Immunol (2013) 190:1113-24. doi:10.4049/jimmunol.1201497
67. Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol (2005) 175:112-23.
68. Yan J, Corbitt N, Pankhong P, Shin T, Khan A, Sardesai NY, et al. Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine. Vaccine (2011) 29:7173-81. doi:10.1016/j.vaccine.2011.05.076
69. Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, Weiner DB. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine (2007) 25:2984-9. doi:10.1016/j.vaccine.2007.01.063
70. Chen MW, Liao HY, Huang Y, Jan JT, Huang CC, Ren CT, et al. Broadly neutralizing DNA vaccine with specific mutation alters the antigenicity and sugar-binding activities of influenza hemagglutinin. Proc Natl Acad Sci U S A (2011) 108:3510-5. doi:10.1073/pnas.1019744108
71. Cukjati D, Batiuskaite D, Andre F, Miklavcic D, Mir LM. Real time electroporation control for accurate and safe in vivo non-viral gene therapy. Bioelectrochemistry (2007) 70:501-7. doi:10.1016/j.bioelechem.2006.11.001
72. Trollet C, Bloquel C, Scherman D, Bigey P. Electrotransfer into skeletal muscle for protein expression. Curr Gene Ther (2006) 6:561-78. doi:10.2174/156652306778520656
73. Becker SM, Kuznetsov AV. Local temperature rises influence in vivo electroporation pore development: a numerical stratum corneum lipid phase transition model. J Biomech Eng (2007) 129:712-21. doi:10.1115/1.2768380
74. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 23:421-9. doi:10.1016/j.coi.2011.03.008
75. Babiuk S, Baca-Estrada ME, Foldvari M, Middleton DM, Rabussay D, Widera G, et al. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol (2004) 110:1-10. doi:10.1016/j.jbiotec.2004.01.015
76. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol (2000) 164:4635-40.
77. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner DB. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine (2008) 26:440-8. doi:10.1016/j.vaccine.2007.10.041
78. Dolter KE, Evans CF, Ellefsen B, Song J, Boente-Carrera M, Vittorino R, et al. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Vaccine (2011) 29:795-803. doi:10.1016/j.vaccine.2010.11.011
79. Khan AS, Pope MA, Draghia-Akli R. Highly efficient constant-current electroporation increases in vivo plasmid expression. DNA Cell Biol (2005) 24:810-8. doi:10.1089/dna.2005.24.810
80. van Drunen Little-van den Hurk S, Lawman Z, Snider M, Wilson D, van den Hurk JV, Ellefsen B, et al. Two doses of bovine viral diarrhea virus DNA vaccine delivered by electroporation induce long-term protective immune responses. Clin Vaccine Immunol (2013) 20:166-73. doi:10.1128/CVI.00565-12
81. Tollefsen S, Vordermeier M, Olsen I, Storset AK, Reitan LJ, Clifford D, et al. DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants. Scand J Immunol (2003) 57:229-38. doi:10.1046/j.1365-3083.2003.01218.x
82. Medi BM, Hoselton S, Marepalli RB, Singh J. Skin targeted DNA vaccine delivery using electroporation in rabbits. I: efficacy. Int J Pharm (2005) 294:53-63. doi:10.1016/j.ijpharm.2004.12.014
83. Ogunremi O, Pasick J, Kobinger GP, Hannaman D, Berhane Y, Clavijo A, et al. A single electroporation delivery of a DNA vaccine containing the hemagglutinin gene of Asian H5N1 avian influenza virus generated a protective antibody response in chickens against a North American virus strain. Clin Vaccine Immunol (2013) 20:491-500. doi:10.1128/CVI.00577-12
84. Hirao LA, Wu L, Satishchandran A, Khan AS, Draghia-Akli R, Finnefrock AC, et al. Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther (2010) 18:1568-76. doi:10.1038/mt.2010.112
85. Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine (2010) 28:1056-61. doi:10.1016/j.vaccine.2009.10.111
86. Hirao LA, Draghia-Akli R, Prigge JT, Yang M, Satishchandran A, Wu L, et al. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis (2011) 203:95-102. doi:10.1093/infdis/jiq017
87. Ferraro B, Talbott KT, Balakrishnan A, Cisper N, Morrow MP, Hutnick NA, et al. Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA. Infect Immun (2013) 81. doi:10.1128/IAI.00180-13
88. Kumar R, Nyakundi R, Karinki T, Ozwara H, Nyamongo O, Mlambo G, et al. Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons. Vaccine (2013) 31:3140-7. doi:10.1016/j.vaccine.2013.05.006
89. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med (2012) 4:155ra138. doi:10.1126/scitranslmed.3004414
90. de Jong A, O'Neill T, Khan AY, Kwappenberg KMC, Chisholm SE, Whittle NR, et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine (2002) 20:3456-64. doi:10.1016/S0264-410X(02)00350-X
91. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, et al. Safety and immunogenicity of TA-HPV, a recombinant Vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 8:3676-85.
92. Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol (2004) 103:317-26. doi:10.1097/01.AOG.0000110246.93627.17
93. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 14:169-77. doi:10.1158/1078-0432.CCR-07-1881
94. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res (2009) 15:361-7. doi:10.1158/1078-0432.CCR-08-1725
95. Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One (2011) 6:e19252. doi:10.1371/journal.pone.0019252
96. Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther (2009) 20:1269-78. doi:10.1089/hum.2009.067
97. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol (1998) 16:867-70. doi:10.1038/nbt0998-867
98. Zucchelli S, Capone S, Fattori E, Folgori A, Di Marco A, Casimiro D, et al. Enhancing B-and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol (2000) 74:11598-607. doi:10.1128/JVI.74.24.11598-11607.2000
99. Selby M, Goldbeck C, Pertile T, Walsh R, Ulmer J. Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol (2000) 83:147-52. doi:10.1016/S0168-1656(00)00308-4
100. Drabick JJ, Glasspool-Malone J, King A, Malone RW. Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol Ther (2001) 3:249-55. doi:10.1006/mthe.2000.0257
101. Glasspool-Malone J, Somiari S, Drabick JJ, Malone RW. Efficient nonviral cutaneous transfection. Mol Ther (2000) 2:140-6. doi:10.1006/mthe.2000.0107
102. Choi SO, Kim YC, Park JH, Hutcheson J, Gill HS, Yoon YK, et al. An electrically active microneedle array for electroporation. Biomed Microdevices (2010) 12:263-73. doi:10.1007/s10544-009-9381-x
103. Lin F, Shen X, Kichaey G, Mendoza JM, Yang M, Armendi P, et al. Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum Gene Ther Methods (2012) 23:157-68. doi:10.1089/hgtb.2011.209
104. Wan YY, Flavell RA. How diverse-CD4 effector T cells and their functions. J Mol Cell Biol (2009) 1:20-36. doi:10.1093/jmcb/mjp001
105. Pitta MG, Romano A, Cabantous S, Henri S, Hammad A, Kouriba B, et al. IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest (2009) 119:2379-87. doi:10.1172/JCI38813
106. Ghosh K, Sharma G, Saha A, Kar S, Das PK, Ukil A. Successful therapy of visceral Leishmaniasis with curdlan involves T-helper 17 cytokines. J Infect Dis (2013) 207:1016-25. doi:10.1093/infdis/jis771
107. Priebe GP, Walsh RL, Cederroth TA, Kamei A, Coutinho-Sledge YS, Goldberg JB, et al. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J Immunol (2008) 181:4965-75.
108. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol (2007) 8:369-77. doi:10.1038/ni1449
109. Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity (1995) 2:129-35. doi:10.1016/S1074-7613(95)80001-8
110. Okada E, Sasaki S, Ishii N, Aoki I, Yasuda T, Nishioka K, et al. Intranasal immunization of a DNA vaccine with IL-12-and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol (1997) 159:3638-47.
111. Kim JJ, Simbiri KA, Sin JI, Dang K, Oh J, Dentchev T, et al. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cytokine Res (1999) 19:77-84. doi:10.1089/107999099314441
112. Sin JI, Kim JJ, Ugen KE, Ciccarelli RB, Higgins TJ, Weiner DB. Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes. Eur J Immunol (1998) 28:3530-40. doi:10.1002/(SICI)1521-4141(199811)28:11<3530::AID-IMMU3530>3.0.CO;2-C
113. Sin JI, Sung JH, Suh YS, Lee AH, Chung JH, Sung YC. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene. Vaccine (1997) 15:1827-33. doi:10.1016/S0264-410X(97)88856-1
114. Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol (1997) 158:1231-7.
115. Barouch DH, Letvin NL, Seder RA. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev (2004) 202:266-74. doi:10.1111/j.0105-2896.2004.00200.x
116. Sin J, Kim JJ, Pachuk C, Satishchandran C, Weiner DB. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J Virol (2000) 74:11173-80. doi:10.1128/JVI.74.23.11173-11180.2000
117. Kim JJ, Nottingham LK, Sin JI, Tsai A, Morrison L, Oh J, et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest (1998) 102:1112-24. doi:10.1172/JCI3986
118. Song R, Liu S, Leong KW. Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines. Mol Ther (2007) 15:1007-15. doi:10.1038/mt.sj.6300129
119. Nguyen-Hoai T, Hohn O, Vu MD, Baldenhofer G, Saved Ahmed MS, Dorken B, et al. CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC. Cancer Gene Ther (2012) 19:880-7. doi:10.1038/cgt.2012.78
120. Ma K, Xu W, Shao X, Yue Y, Hu L, Xu H, et al. Coimmunization with RANTES plasmid polarized Th1 immune responses against hepatitis B virus envelope via recruitment of dendritic cells. Antiviral Res (2007) 76:140-9. doi:10.1016/j.antiviral.2007.06.012
121. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today (1994) 15:321-31. doi:10.1016/0167-5699(94)90080-9
122. Lanier LL, O'Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K, et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol (1995) 154:97-105.
123. Tsuji T, Hamajima K, Ishii N, Aoki I, Fukushima J, Xin KQ, et al. Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen. Eur J Immunol (1997) 27:782-7. doi:10.1002/eji.1830270329
124. Corr M, Tighe H, Lee D, Dudler J, Trieu M, Brinson DC, et al. Costimulation provided by DNA immunization enhances antitumor immunity. J Immunol (1997) 159:4999-5004.
125. Kim JJ, Bagarazzi ML, Trivedi N, Hu Y, Kazahaya K, Wilson DM, et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol (1997) 15:641-6. doi:10.1038/nbt0797-641
126. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 8:239-45. doi:10.1038/ni1443
127. Song MY, Park SH, Nam HJ, Choi DH, Sung YC. Enhancement of vaccine-induced primary and memory CD8+ T-cell responses by soluble PD-1. J Immunother (2011) 34:297-306. doi:10.1097/CJI.0b013e318210ed0e
128. Zhou J, Cheung AKL, Tan Z, Wang H, Yu W, Du Y, et al. PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. J Clin Invest (2013) 123:2629-42. doi:10.1172/JCI64704
129. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, et al. Interleukin-12: biological properties and clinical applications. Clin Cancer Res (2007) 13:4677-85. doi:10.1158/1078-0432.CCR-07-0776
130. Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K, Wang B, et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol (1997) 158:816-26.
131. Boyer JD, Robinson TM, Kutzler MA, Parkinson R, Calarota SA, Sidhu MK, et al. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol (2005) 34:262-70. doi:10.1111/j.1600-0684.2005.00124.x
132. Schadeck EB, Sidhu M, Egan MA, Chong SY, Piacente P, Masood A, et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine (2006) 24:4677-87. doi:10.1016/j.vaccine.2005.10.035
133. Boyer JD, Cohen AD, Ugen KE, Edgeworth RL, Bennett M, Shah A, et al. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids. AIDS (2000) 14:1515-22. doi:10.1097/00002030-200007280-00007
134. Chong SY, Egan MA, Kutzler MA, Megati S, Masood A, Roopchard V, et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine (2007) 25:4967-82. doi:10.1016/j.vaccine.2006.11.070
135. Winstone N, Wilson AJ, Morrow G, Boggiano C, Chiuchiolo MJ, Lopez M, et al. Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. J Virol (2011) 85:9578-87. doi:10.1128/JVI.05060-11
136. Jalah R, Patel V, Kulkarni V, Rosati M, Alicea C, Ganneru B, et al. IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. Hum Vaccin Immunother (2012) 8:1620-9. doi:10.4161/hv.21407
137. Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, et al. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One (2012) 7:e29231. doi:10.1371/journal.pone.0029231
138. Shan MM, Liu KZ, Fang HL, Chen Z. DNA immune responses induced by codelivery of IL-12 expression vectors with hepatitis C structural antigens. Hepatobiliary Pancreat Dis Int (2002) 1:553-7.
139. Sin JI, Kim JJ, Arnold RL, Shroff KE, McCallus D, Pachuk C, et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol (1999) 162:2912-21.
140. Khosroshahi KH, Ghaffarifar F, Sharifi Z, D'Souza S, Dalimi A, Hassan ZM, et al. Comparing the effect of IL-12 genetic adjuvant and alum non-genetic adjuvant on the efficiency of the cocktail DNA vaccine containing plasmids encoding SAG-1 and ROP-2 of Toxoplasma gondii. Parasitol Res (2012) 111:403-11. doi:10.1007/s00436-012-2852-7
141. Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid IL-12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 208:818-29. doi:10.1093/infdis/jit236